JNJ · News · 20260916N
Portfolio Reshaping (M&A / Divestiture)
JOHNSON & JOHNSON · 2026-09-16 · Importance 34 · Surprise 42 · In source text
Johnson & Johnson is selling the assets of Laminar, a company it acquired in November 2023 for its left atrial appendage closure device. The divestiture follows suspension of Laminar’s pivotal trial because of safety concerns. Jaguar LAA, a newly formed company backed by Santé Ventures, is acquiring the assets and plans to continue developing the technology. J&J said the transaction supports its strategy of concentrating resources on high-growth areas within its MedTech portfolio.
Key facts
- Johnson & Johnson is selling the assets of Laminar, a company it acquired in November 2023, after suspending a pivotal trial due to safety concerns. source
- The Laminar assets are being bought by Jaguar LAA, a newly formed company backed by Santé Ventures, which plans to continue developing the technology. source
- Johnson & Johnson said the decision to sell the Laminar assets is part of its strategy to focus resources on high-growth areas within its medtech portfolio. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| assets | negative | committed | — | The Laminar assets are being bought by Jaguar LAA, a newly formed company backed by Santé Ventures, which plans to continue developing the… |